{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:24:48Z","timestamp":1792855488386,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.08.035","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:18:42Z","timestamp":1788995922000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-6166","authenticated-orcid":false,"given":"Stacy E.","family":"Croteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-0802","authenticated-orcid":false,"given":"Susan","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-5020","authenticated-orcid":false,"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.035_bib1","series-title":"Clinical investigation of recombinant and human plasma-derived factor VIII products \u2013 Scientific guideline","year":"2019"},{"key":"10.1016\/j.jtha.2026.08.035_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.12750","article-title":"A systematic review of definitions and reporting of bleeding outcome measures in haemophilia","volume":"21","author":"Chai-Adisaksopha","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.035_bib3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/cts.12794","article-title":"Annual bleeding rates: pitfalls of clinical trial outcomes in hemophilia patients","volume":"13","author":"Keipert","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2026.08.035_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.035_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/hae.12667","article-title":"Differentiating between signs of intra-articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature","volume":"21","author":"Timmer","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.035_bib9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1160\/TH17-03-0166","article-title":"Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A","volume":"117","author":"Meunier","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.035_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib16","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII Kids: BAY 94-9027 (PEGylated recombinant factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.035_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jth.13360","article-title":"Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial","volume":"14","author":"Carcao","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib20","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib21","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","article-title":"Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study","volume":"4","author":"Fischer","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.08.035_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1160\/TH16-03-0179","article-title":"Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial","volume":"116","author":"Kenet","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib29","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.08.035_bib30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.08.035_bib31","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.08.035_bib32","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial","volume":"146","author":"Matino","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.035_bib34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.035_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12782","article-title":"Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3","volume":"6","author":"Callaghan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.035_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2026.08.034","article-title":"Recommendations for harmonizing definition, recording and reporting of the annual bleeding rate (ABR) in hemophilia: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders","author":"Srivastava","year":"2026","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600560X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600560X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:29:15Z","timestamp":1790825355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362600560X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S153878362600560X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.035","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}